Anti-CD3 drug keeps diabetes at bay
Sign Up to like & getrecommendations! Published in 2019 at "Nature Biotechnology"
DOI: 10.1038/d41587-019-00025-4
Abstract: No drug has ever delayed islet cell destruction. Now that teplizumab has, the challenge turns to identifying eligible recipients for the treatment. No drug has ever delayed islet cell destruction. Now that teplizumab has, the… read more here.
Keywords: keeps diabetes; anti cd3; diabetes bay; drug ... See more keywords